Related Experiment Videos
[Prostate cancer after prostatectomy for benign prostatic hyperplasia]
Lixin Hua1, Jiexiu Zhang, Hongfei Wu
1Department of Urology, the First Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210029, China. hlx5858@163.com
Zhonghua Nan Ke Xue = National Journal of Andrology
|September 15, 2004
Summary
Prostatectomy for benign prostatic hyperplasia (BPH) does not prevent prostate cancer. Diagnosis relies on prostate-specific antigen (PSA) and digital rectal examination (DRE) in patients with a history of BPH surgery.
Area of Science:
- Urology
- Oncology
Context:
- Prostatectomy for benign prostatic hyperplasia (BPH) is a common procedure.
- Prostate cancer can develop after BPH surgery, necessitating specific diagnostic and treatment strategies.
Purpose:
- To investigate the diagnosis and treatment of prostate cancer in patients who previously underwent prostatectomy for BPH.
- To evaluate the efficacy of current diagnostic methods and treatment approaches for this patient cohort.
Summary:
- This study reviewed 12 cases of prostate cancer diagnosed after BPH prostatectomy, with a mean interval of 5.6 years.
- Common symptoms included dysuria, hematuria, and pain. Elevated prostate-specific antigen (PSA) and abnormal digital rectal examination (DRE) were key diagnostic indicators.
- Treatment involved combined androgen blockade in most cases, with some receiving surgical castration or transurethral resection of the prostate (TURP).
Impact:
- Prostatectomy for BPH does not preclude the development of prostate cancer.
- PSA and DRE are crucial for early detection of prostate cancer post-BPH surgery.
- Effective management strategies are essential for improving outcomes in these patients.